menu
    • menu

    Company profile for Renexxion

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ​Renexxion is committed to delivering benefits to patients in need by developing naronapride to approval and to becoming a leading GI biopharmaceutical company. Renexxion Innovation There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class of 5-HT4 agonists has shown to be effective fo...
    ​Renexxion is committed to delivering benefits to patients in need by developing naronapride to approval and to becoming a leading GI biopharmaceutical company. Renexxion Innovation There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class of 5-HT4 agonists has shown to be effective for a range of these disorders.Renexxion Ireland is committed to delivering benefits to patients in need by developing naronapride to approval and to becoming a leading GI biopharmaceutical company.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RenexxionIreland Flag
    Country
    Country
    Ireland
    Address
    Address
    Carlton House, 4th Floor Henry Street Limerick V94 FD80
    Telephone
    Telephone
    +353 61 539121
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.rnexltd.ie/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/renexxion/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Renexxion, Dr. Falk Complete Ph2b Gastroparesis Trial
    Renexxion, Dr. Falk Complete Ph2b Gastroparesis Trial

    27 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/27/3088578/0/en/Renexxion-Ireland-Ltd-and-Dr-Falk-Pharma-GmbH-Announce-Completion-of-Enrollment-of-the-Global-Phase-2b-Study-Evaluating-Naronapride-in-Gastroparesis-MOVE-IT.html

    GLOBENEWSWIRE
    27 May 2025
    Share Share
    Relief Therapeutic Provides Update on Renexxion Transaction
    Relief Therapeutic Provides Update on Renexxion Transaction

    27 Dec 2024

    // ACCESSWIRE

    https://www.accesswire.com/960280/relief-therapeutics-provides-update-on-potential-transaction-with-renexxion

    ACCESSWIRE
    27 Dec 2024
    Share Share
    Renexxion And Dr. Falk Expand Naronapride Study, Dose First US Patient
    Renexxion And Dr. Falk Expand Naronapride Study, Dose First US Patient

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929188/0/en/Renexxion-Ireland-Ltd-and-Dr-Falk-Pharma-GmbH-Announce-Expansion-of-the-Phase-2b-MOVE-IT-Study-of-Naronapride-in-Gastroparesis-and-Dosing-of-the-First-United-States-Patient.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Renexxion Announce FDA Clearance of the Naronapride to Treat Gastroparesis
    Renexxion Announce FDA Clearance of the Naronapride to Treat Gastroparesis

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853148/0/en/Renexxion-Ireland-Ltd-and-Dr-Falk-Pharma-GmbH-Announce-FDA-Clearance-of-the-Investigational-New-Drug-Application-for-Naronapride-to-Treat-Gastroparesis-and-Subsequent-Expansion-of-.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Renexxion Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
    Renexxion Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories

    07 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/07/2825114/0/en/Renexxion-Ireland-s-European-Partner-Dr-Falk-Pharma-GmbH-has-Elected-PPI-non-responsive-Symptomatic-GERD-as-the-Second-Naronapride-Indication-to-Develop-and-Commercialize-in-their-.html

    GLOBENEWSWIRE
    07 Feb 2024
    Share Share
    Renexxion to Present at the Oppenheimer 34áµ—Ê° Annual Healthcare Conference
    Renexxion to Present at the Oppenheimer 34áµ—Ê° Annual Healthcare Conference

    01 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/01/2822007/0/en/Renexxion-to-Present-at-the-Oppenheimer-34%E1%B5%97%CA%B0-Annual-Healthcare-Life-Sciences-Conference.html

    GLOBENEWSWIRE
    01 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search